ClinicalTrials.gg
Status unknownNCT01906749COACSUpdated Jul 24, 2013

Colchicine for Acute Coronary Syndromes

A Phase 4 interventional study of Colchicine and Placebo in Acute Coronary Syndrome, sponsored by Maria Vittoria Hospital. Status unknown at 3 sites in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-07-24.

Sponsored by Maria Vittoria Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Multicenter, double blind, randomized trial to assess the effect of low-dose colchicine (0.5mg/day) on overall mortality, new coronary syndromes, and ischemic stroke at 2 years after an acute coronary syndrome. The study hypothesis is that colchicine may reduce the specified combined endpoint from 16% to 7-8% at a 2-years follow-up.

Read the detailed description

Multicenter, double-blind randomized trial to evaluate the efficacy of low dose colchicine (0.5mg once daily for 2 years) to reduce the incidence of subsequent overall mortality, new acute coronary syndromes, and ischemic stroke in patients admitted for an acute coronary syndrome.

02

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Acute coronary syndrome
  • Colchicine
03

In context

Acute Coronary Syndrome

1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

This study's planned enrollment of 500 is above the median of 200 across 865 interventional studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Maria Vittoria Hospital is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18years
  • Acute coronary syndrome (unstable angina or acute myocardial infarction)
  • > 2 years
  • Absence of to colchicine

Exclusion criteria

Exclusion Criteria:

  • Colchicine treatment for any cause
  • Severe liver disease
  • Renal insufficiency with creatinine>150mmol/l or \<30ml/min/1.73m2
  • Known cancer
  • Chronic inflammatory bowel disease
  • treatment with cyclosporine
  • allergy or to colchicine
  • pregnancy or lactating woman or woman with without valid
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Active comparator
    Colchicine

    Colchicine 0.5mg once daily for 24 months

    Drug: Colchicine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall mortality, new acute coronary syndrome, and ischemic stroke.

    Time frame: 24 months

Secondary outcomes

  1. Mortality

    Secondary outcome measures will contain each issue of the combined primary endpoint as separate outcome.

    Time frame: 24 months

  2. New acute coronary syndrome (unstable angina and myocardial infarction)

    Time frame: 24 months

  3. Ischemic Stroke

    Time frame: 24 months

07

Study locations

2 of 3 sites recruiting
  • Cardiology Dpt.
    Rivoli, Torino 10098, Italy
    Not yet recruiting
    • Ferdinando Varbella, MD · Contact011 95511
    • Ferdinando Varbella, MD · Principal investigator
  • Cardiology Dpt.Maria Vittoria Hospital
    Torino, 10141, Italy
    Recruiting
    • Alessandra Chinaglia, MD · Contact+39011439
    • Luisella Coda, MD · Sub investigator
    • Alessandra Chinaglia, MD · Principal investigator
  • Cardiology Dpt.San Giovanni Bosco Hospital
    Torino, 10141, Italy
    Recruiting
    • Patrizia Noussan, MD · Contact+39 240
    • Patrizia Noussan, MD · Principal investigator
08

References and documents

Publications

  • Silvis MJM, Demkes EJ, Fiolet ATL, Dekker M, Bosch L, van Hout GPJ, Timmers L, de Kleijn DPV. Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction. J Cardiovasc Transl Res. 2021 Feb;14(1):23-34. doi: 10.1007/s12265-020-10049-w. Epub 2020 Jul 9. PubMed 32648087 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2013
First posted
Jul 24, 2013
Start
Jun 2013
Primary completionEst.
Jun 2016
CompletionEst.
Jun 2016
Last update
Jul 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01906749
Lead sponsor
Maria Vittoria Hospital
Responsible party
Massimo Imazio (MD, Maria Vittoria Hospital) — Principal investigator
First posted
Jul 24, 2013
Start date
Jun 2013
Primary completion
Jun 2016 (estimated)
Completion
Jun 2016 (estimated)
Last update
Jul 24, 2013

Study contacts

Massimo Imazio, MD
Contact
massimo_imazio@yahoo.it
+39011439 ext. 3391
Massimo Imazio, MD
study chair · Cardiology Dpt.Maria Vittoria Hospital, Torino, Italy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion